No Data
No Data
Estimating The Intrinsic Value Of Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE:600594)
Guizhou Yibai Pharmaceutical CFO Steps Down; Successor Named
Guizhou Yibai Pharmaceutical (600594.SH): There is currently no research and development plan for drugs against Monkey Pox infection.
Guizhou Yibai Pharmaceutical (600594.SH) stated on the interactive platform on September 6th that the company currently has no plans to develop drugs for monkey teasing infections.
Guizhou Yibai Pharmaceutical (600594.SH): Jiang Xianhong resigned from the position of Chief Financial Officer of the company, and Zeng Xianti took over.
On September 6th, Guizhou Yibai Pharmaceutical (600594.SH) announced that the board of directors received the written resignation report from Mr. Jiang Xianhong, the deputy general manager, financial officer, and board secretary of the company. Due to personal reasons, Mr. Jiang Xianhong applied to resign from the position of financial officer of the company, and his resignation report will take effect from the date of delivery to the board of directors. After resigning as the financial officer, Mr. Jiang Xianhong will continue to serve as the deputy general manager and board secretary of the company. The company has decided to appoint Mr. Zeng Xianti as the financial officer of the company, with a term from the date of approval by this board of directors until the expiration of the eighth session of the board of directors.
Guizhou Yibai Pharmaceutical (600594.SH): Obtained the registration certificate for Puleeshafu Injection
Guizhou Yibai Pharmaceutical (600594.SH) announced that the company has received the "Drug Registration Certificate" of Purefsiaxif Injection, which was approved and issued by the National Medical Products Administration. Purefsiaxif Injection is used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) into peripheral blood, facilitating the collection and transplantation of HSC in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
Guizhou Yibai Pharmaceutical (600594.SH): has repurchased 0.64% of the company's shares.
As of the end of August 2024, Guizhou Yibai Pharmaceutical (600594.SH) announced that it has repurchased a total of 5,037,400 shares of the company through centralized auction trading, accounting for 0.64% of the total share capital. The highest repurchase price was 3.06 yuan per share, and the lowest price was 2.89 yuan per share. The total amount paid was RMB 14,997,308 (excluding transaction commission and other transaction fees).
No Data
No Data